UFT and Mitomycin Plus Tamoxifen for Stage II, ER-Positive Breast Cancer
ByYoshinobu Hata, MD, PhD,Junichi Uchino, MD, PhD,Kazuaki Asaishi, MD, PhD,Yoshihiko Kubo, MD, PhD,Michio Mito, MD, PhD,Tatsuzo Tanabe, MD, PhD,Masami Ogita, MD, PhD,Koichi Hirata, MD
Published: | Updated:
A trial was designed to examine the combination of UFT and mitomycin (Mutamycin) plus tamoxifen (Nolvadex) as postoperative adjuvant therapy in the treatment of patients with stage II, estrogen receptor (ER)-positive